

*Recd  
9-27-02*

# OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ozaki et al.

Serial No.: 09/214,881

Filed: June 7, 1999

For: DIAGNOSTIC DRUGS FOR AUTO  
IMMUNE DISEASE

Group Art Unit: 1644

Examiner: Patrick Nolan

Att'y Docket: 13240.0004.NPUS00

Client Docket: F5-01F03832/  
KA016-1 US RCE


## REQUEST FOR CONTINUED EXAMINATION (RCE)

Commissioner for Patents  
Washington, D.C. 20231

**CERTIFICATE OF TRANSMISSION**  
37 C.F.R. 1.8

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office to (703) 746-5303 on the date below:

27 SEP 02  
Date

  
Signature

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above identified application.

1. Submission required under 37 C.F.R. § 1.114

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on .
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on .
  - iii.  Other
- b.  Enclosed
  - i.  Amendment/reply
  - ii.  Affidavit(s)/Declaration(s)
  - iii.  Information Disclosure Statement (IDS)

d9/2002 G

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: § Group Art Unit: 1644  
 Ozaki et al. § Examiner: Patrick Nolan  
 Serial No.: 09/214,881 § Att'y Docket: 13240.0004.NPUS00  
 Filed: June 7, 1999 § Client Docket: F5-01F03832/  
 For: DIAGNOSTIC DRUGS FOR AUTO KA016-1 US RCE  
 IMMUNE DISEASE §

PRELIMINARY AMENDMENT

Commissioner for Patents  
 Washington, D.C. 20231

**CERTIFICATE OF TRANSMISSION**  
 37 C.F.R. 1.8

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office to (703) 746-5303 on the date below:

27 SEP 02   
 Date Signature

Sir:

Please amend this application as follows:

IN THE CLAIMS:

Please enter the following rewritten claim. A marked up version of the rewritten claim, and a clean version of all pending claims are attached at the end of this document.

*Sub H1* 6. (Three times amended) The kit of claim 4, wherein:  
 the polypeptide having an amino acid sequence homology of 90% or more with SEQ ID  
 NO:1 is selected from human, bovine, porcine, or rat HMG-1; and  
 the polypeptide having an amino acid sequence homology of 80% or more with SEQ ID  
 NO:2 is selected from human, bovine, porcine, chicken, mouse, or rat HMG-2.